glp-1 agonists blindness risk π Optometrists are warning drugs may pose these types of rare risks π β¬οΈ Details in comments Benefit-Risk Assessment of GLP-1 Receptor
Description
Exploring connections between weight-loss medications and thyroid cancer: a look at the FDA adverse event reporting system database
Across all trials, 41 deaths occurred in individuals receiving tirzepatide ( n = 4573) and 39 in the comparator arms ( n = 2151)
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity (2020)
Join thousands of Healthineers in restoring your hair and confidence
the half-life of Semaglutide is 57 days, so the drug should be ceased ~ 6 weeks before conception) [22, 34]
